ARAMINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Aramine, and when can generic versions of Aramine launch?
Aramine is a drug marketed by Merck and is included in one NDA.
The generic ingredient in ARAMINE is metaraminol bitartrate. There is one drug master file entry for this compound. Additional details are available on the metaraminol bitartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Aramine
A generic version of ARAMINE was approved as metaraminol bitartrate by AZURITY on August 24th, 2021.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ARAMINE?
- What are the global sales for ARAMINE?
- What is Average Wholesale Price for ARAMINE?
Summary for ARAMINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 52 |
| DailyMed Link: | ARAMINE at DailyMed |
US Patents and Regulatory Information for ARAMINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | ARAMINE | metaraminol bitartrate | INJECTABLE;INJECTION | 009509-002 | Dec 22, 1987 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
